Our aim was to identify the possible mutations of the natriuretic peptide precursor B (NPPB) gene in a family with hereditary hypertension, and determine whether the mutations are associated with the antihypertensive effect of sodium nitroprusside. The subjects included one family with hereditary hypertension, 36 cases of sporadic hypertension and 120 healthy controls. The 5 0 -flanking sequence of NPPB was amplified with PCR, and the presence of mutations was analyzed by direct sequencing. Patients with hypertension were treated with sodium nitroprusside and blood pressure data and serum B-type natriuretic peptide (BNP) levels were measured. A novel complex mutation in 5 0 -flanking sequence of the NPPB gene was detected in three patients (II 2, III 2, and III 5) of the hypertension family, which included c.-1195_ -1176 insert 5 0 -CCTTCTTTCTTTCTTTCTTT-3 0 , c.-1208 T4A, c.-1214 T4C, and c.-1216 T4A. Patients with this mutation were less sensitive to sodium nitroprusside treatment. Sporadic hypertension patients (without NPPB gene mutation) and patients with the c.-1181 T4A point mutation were sensitive to sodium nitroprusside treatment. BNP levels of patients with the complex mutation were significantly lower than that of sporadic hypertension patients and c.-1181 T4A mutation patients before and during the early stage of sodium nitroprusside treatment. The complex mutation of the NPPB gene might be an etiological factor of hereditary malignant hypertension, and it is associated with low sensitivity to the antihypertensive effect of sodium nitroprusside. Keywords: B-type natriuretic peptide; insertion mutation; point mutation; malignant hypertension; sodium nitroprusside
INTRODUCTION
The etiology of most types of hypertension is unknown, while genetic factors account for 30-50% of cases of primary hypertension. [1] [2] [3] Moreover, the sensitivity of individuals to hypotensive drugs is associated with genetic heterogeneity. [1] [2] [3] [4] [5] Therefore, the relationship between the genetic background and the onset of hypertension and effects of antihypertensive drugs has become a focus of research. In particular, genes related to sodium and water balance, and blood vessel dilation have attracted attention. 6 Natriuretic peptide, also called B-type natriuretic peptide (BNP), promotes sodium elimination and urination and exerts a strong vasodilator effect. 7 In patients with essential hypertension, plasma BNP levels are increased. As BNP has a role in relaxing blood vessels and lowering blood pressure (BP), BNP elevation during an increase in BP is a compensatory reaction of the body. 8, 9 Plasma levels of BNP increase in various pathological conditions, 10 and can be used for evaluation of disease status, 10 assessment of therapeutic effectiveness 11, 12 and prognosis in patients with hypertension and acute coronary syndrome. [13] [14] [15] [16] Elevation of N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is associated with coronary heart disease and pulmonary hypertension, and increased morbidity and mortality in patients with stable coronary disease. 13, 15 Mutations of the natriuretic peptide precursor B (NPPB) gene lead to alterations in the function or expression level of BNP, and studies have shown correlations between NPPB gene polymorphisms and cardiovascular disease. 5, 17 The deletion of sequences between À 1288 and À 1095 has been shown to reduce transcriptional activity of the NPPB gene to B30% of the normal activity. 18 Association between the variable number of tandem repeat (VNTR) polymorphism (a tandem repeat of TTTC) in the 5 0 -flanking region of the NPPB gene and essential hypertension was found in Japanese women; the frequency of the 16-repeat allele was significantly lower in the female essential hypertension patients than in the female normotensive subjects. 8 The concentration of BNP has been shown to be higher in preeclamptic women than normal controls, and the elevation was associated with the (TTTC) small-tandem repeat of the NPPB gene. 19 Takeishi et al. 20 reported significant associations of the eight single-nucleotide polymorphisms surrounding the entire NPPB gene with plasma BNP levels. Newton-Cheh et al. 21 reported that the alleles of rs5068 and rs198358 that were associated with increased natriuretic concentrations were also associated with lower systolic and diastolic BP. Other studies have also found associations of NPPB gene polymorphisms and BNP levels. 22, 23 Recently, we discovered a novel complex mutation of NPPB and a point mutation in one family with hereditary hypertension. The purpose of this study was to determine the association between mutations in the NPPB gene and the antihypertensive effect of sodium nitroprusside.
SUBJECTS AND METHODS Participants
The subjects included one family with malignant hypertension (7 subjects; Figure 1 ), 36 subjects with sporadic malignant hypertension patients (23 males, 13 females; median age, 51.2 ± 10.8 years), and 120 healthy controls (62 males, 58 females; median age 49.7±10.2 years). This study was approved by the Ethics Committee of our hospital, and all subjects provided written informed consent for their participation.
Inclusion and exclusion criteria
Inclusion criteria for patients with malignant hypertension were systolic BP (SBP) 4180 mm Hg, diastolic BP (DBP) 4120 mm Hg, and no antihypertensive drugs for the 2 weeks preceding the study. Exclusion criteria were secondary hypertension, severe anemia, valvular heart disease, congenital heart disease, cardiomyopathy, arteriovenous fistula, constrictive pericarditis, pericardial effusion, severe arrhythmia, peripheral vascular disease, diabetes mellitus, myocardial infarction, congestive heart failure and other systemic diseases, which would increase the risk of the examination to an unacceptable level. Inclusion criteria for controls were SBP o140 mm Hg, DBP o90 mm Hg, and no evidence on physical examination or laboratory studies of cardiovascular, cerebrovascular, renal, hepatic and endocrine disease.
DNA extraction and PCR
In all, 2 ml of peripheral venous blood was collected from each subject. DNA was extracted from peripheral blood using the Wizard Genomic DNA Purification Kit (Promega Corporation, Madison, WI, USA) following the manufacturer's instructions.
Primers were designed using Primer Express software (Life Technologies, Shanghai, China), and synthesized by Shanghai Shenggong Bioengineering Services Ltd (Shanghai, China). A pair of primers was designed as follows:
0 . The amplification products of the primers were DNA sequences with a length of 429 bp that located À 1299 to À 895 upstream of the transcription start site of the NPPB gene. The total volume of the PCR reaction was 50 ml, including 50 ng DNA, 0.06 mol l À 1 primers, 0.2 mmol l À 1 deoxyribonucleotide triphosphate, 2.5 ml 10Â PCR buffer, 2.0 mmol l À 1 magnesium chloride, and 1U Taq enzyme (Promega Company). On the PE9700 thermal cycler (Perkin Elmer, Boston, MA, USA), the cycling conditions were as follows: pre-denaturation at 94 1C for 5 min, followed by denaturation at 94 1C for 30 s, annealing at 58 1C for 30 s and extension at 72 1C for 30 s. After 35 cycles, extension was performed at 72 1C for 7min. Products were electrophoresed on 1.5% agarose gel, and the electrophoresis results were observed. A gel recovery kit (Tiangen Company, Beijing, China) was used, and the products were recovered in accordance with the kit instruction.
Sequencing
PCR products were directly sequenced by Shanghai Shenggong Bioengineering Services Ltd. Sequencing results were compared with the published standard sequence of NPPB on the NCBI website (http:// www.genecards.org/cgi-bin/carddisp.pl?gene=NPPB (GI: 167882799)).
Sodium nitroprusside treatment
Briefly, 25-50 mg of sodium nitroprusside (Beijing Double-Crane Modern Pharmaceutical, Beijing, China) was dissolved in 500 ml of 10% glucose solution, and slowly dripped at a rate of 25-75 mg min À 1 while kept in the dark. BP and heart rate were recorded every 10 min during the first hour, and then hourly. The drip rate was adjusted based on BP. Patient's serum was collected at four time points, and a high-sensitivity electrochemiluminescence technique was used to detect BNP. The four time points were: time point 1, before treatment; time point 2, mean BP (MBP) decreased by 25%; time point 3, MBP returned to normal; time point 4, 24 h after MBP returned to normal.
Ambulatory BP monitoring
A non-invasive portable ambulatory BP monitor (Medilog DX; Oxford Instruments plc, Oxfordshire, UK) was used. The cuff was maintained on the right upper arm of the subjects for 24 h; from 0800 h to 0800 h the next day. A total of 24 h of BP (SBP and DBP) and the heart rate data were recorded with autoinflation for 20 min every 1 h interval during the period from 0600 h to 2200 h and were recorded for 30 min every 1 h interval during the period from 2200 h to 0600 h. The 24 h SBP or 24 h DBP was defined as the mean of all measurements. The subjects were instructed to maintain normal daily work schedules and activity. If extrasystolic beats (4 20%) or incomplete reading (o20 min during the period from 0600 h to 2200 hor o30 min during the period from 2200 h to 0600 h), the test would be repeated the next day.
Statistical analysis
Quantitative data were shown as mean ± s.d. Comparisons among malignant hypertension patients carrying NPPB gene mutations, malignant hypertension group with the normal gene, and the control group were analyzed by one-way analysis of variance with the Student-Newman-Keuls method for comparison between the two groups. Analysis of covariance was used to analyze the difference in the antihypertensive effects of sodium nitroprusside among different genotypes. A value of Po0.05 was considered to indicate statistical significance. All analyses were performed with SPSS version 15.0 statistical software (SPSS Inc., Chicago, IL, USA).
RESULTS

DNA sequence analysis
Three patients in the hereditary hypertension family (II 2, III 2, III 5) were found to be carriers of a previously unreported complex mutation including c.-1195_ -1176 insert 5 0 -CCTTCTTTCTTT CTTTCTTT-3 0 , c.-1208 T4A, c.-1214 T4C and c.-1216 T4A. Figure 2a shows the DNA sequence of the proband (III 5). As shown in Figure 2a , the mutation was heterozygous. Based on the pedigree of the family (Figure 1 ), the mutation sequence of III 2 and III 5 should inherit from the mother (II 2). In addition, a point mutation c.-1181 T4A was found in other hypertension patients in the family (II 2, II 3, III 3, IV 4 and IV 1). The DNA sequence of a normal control is shown in Figure 2b . A normal individual carrying a c.-1190 G4T single-nucleotide polymorphism is shown in Figure 2c .
Demographic characteristics and clinical features
The proband (III 5) was a 35-year-old female with a 2-year history of hypertension. Both of her parents had malignant hypertension. Hypertension was discovered at 3 months of pregnancy when her BP peaked to 230 per 130 mm Hg. Electrocardiogram showed high voltage in the left ventricle. Ultrasound of the kidneys revealed no abnormalities. Urinalysis revealed urine protein 40.3 g l À 1 . Intravenous sodium nitroprusside did not produce an obvious hypotensive effect; a significant effect was achieved after changing to phentolamine.
The demographic characteristics and clinical features of malignant hypertension patients carrying NPPB gene mutations (NPPB gene complex mutation group, n ¼ 3; NPPB gene c.-1181 T4A mutation group, n ¼ 4), malignant hypertension group with the normal gene, and the control group are shown in Table 1 . Hypertension patients with NPPB gene mutations were younger than subjects in the other two groups (Po0.05). The cholesterol level of the control group was significantly lower than that of the two hypertension groups (Po0.05). Both the SBP and DBP of the control group were significantly lower than that of the two hypertension groups (Po0.05). Hypertension patients with NPPB gene mutations had significantly higher mean arterial pressure and pulse pressure than the hypertension patients without NPPB gene mutations and the control group (Po0.05).
A comparison of the clinical features between hypertension patients with the NPPB complex mutation and hypertension patients without the NPPB gene mutation is shown in Table 2 . Results indicated that there was no difference between the two groups in clinical features, including mean arterial pressure and pulse pressure. These data suggested that there were some Mutation of NPPB gene in hypertension patients K Zeng et al differences in clinical features between the NPPB gene complex mutation group and c.-1181 T4A mutation group.
Serum BNP levels Figure 3 shows that patients with NPPB gene c.-1181 T4A point mutations in the NPPB gene have similar baseline BNP as subjects with normal genes. The complex mutation group had a significantly lower serum BNP level than the malignant hypertension group with the normal gene and the NPPB gene c.-1181 T4A mutation groups before treatment (time point 1), and at the time point when MBP had decreased by 25% after sodium nitroprusside treatment (time point 2). In fact, the serum BNP level of the complex mutation group was relatively low before treatment, and there was no significant change between pre-and post-treatment with sodium nitroprusside.
BP changes after administration of sodium nitroprusside Table 3 shows the BP changes after the administration of sodium nitroprusside in hypertensive patients with the normal NPPB gene, NPPB c.-1181 T4A mutation and NPPB complex mutation. After sodium nitroprusside treatment, the change in clinical SBP (DcSBP), the decline rate of cSBP (DcSBP/cSBP1), change in clinical DBP (DcDBP), the decline rate of cDBP (DcDBP/cDBP1), and change in 24 h SBP (D24 h SBP) were significantly lower in hypertension patients with the NPPB complex mutation ( Table 3) . The decline rate of 24 h SBP (D24 h SBP/24 h SBP1) and the decline rate of 24 h DBP (D24 h DBP/24 h DBP1) were significantly lower in both NPPB mutation groups than in the normal gene group. The change in 24 h DBP (D24 h DBP) and decline rate of nighttime SBP (DnSBP/nSBP1) was significantly different among the three groups. There was no significant difference in change in daytime DBP (DdDBP) and the decline rate of dDBP (DdDBP/dDBP1), but the change in nighttime DBP (DnDBP) and the decline rate of nDBP (DnDBP/nDBP1) were significantly lower in both the NPPB mutation groups than in the normal gene group.
DISCUSSION
In the present study, we report a hereditary hypertension family. Three family members had a frame-shifting mutation of the NPPB gene resulting from a 20-nucleotide insertion located at the 5 0 -flanking sequence, which is a well-known regulatory region for transcription. In addition, three novel mutations (c.-1208 T4A, c.-1214 T4C, c.-1216 T4A) occurred upstream of a large insertion mutation. Four family members carried a point mutation c.-1181 T4A. Patients with NPPB gene mutations had relatively high mean arterial pressure and pulse pressure. The complex mutation in the 5 0 -flanking sequence was associated with a reduced plasma level of BNP (Figure 3) . These results are consistent with an important role for the 5 0 -flanking region of the NPPB gene in regulating BP. In addition, the complex mutation of the NPPB gene was associated with a low sensitivity to the antihypertensive effect of sodium nitroprusside. 24 In the JNC6, stage 3 hypertension was defined as SBP X180 mm Hg; DBP X110 mm Hg. However, JNC 7 did not define the BP of malignant hypertension (or stage 3). Based on the review article published by Kitiyakara and Guzman, 25 the range of presenting BP is wide in patients with malignant hypertension, with DBP ranging from 100 to 180 mm Hg and SBP from 150 to 290 mm Hg. Several previous articles have defined malignant hypertension as a DBP 4120 mm Hg. 26, 27 In our study, the inclusion criteria for patients with malignant hypertension were SBP 4180 mm Hg and DBP 4120 mm Hg, which were within the BP range suggested by previous articles.
The NPPB gene was identified in 1985, and is a member of the natriuretic peptide family that includes atrial natriuretic peptide. 7 It is present in human plasma in the form of a specific ring structure, has strong vasodilator effects, and promotes excretion of sodium and urine. For these reasons, it was recognized as a possible candidate genes for hypertension. 1, 6 Ogawa et al. 18 reported that a 1.9 kb region at the 5 0 -flanking sequence maintained the high transcriptional activity of the NPPB gene, and the knockout of a sequence between À 1288 and À 1095 reduced the transcriptional activity to about 30% of normal. These results indicated that the 5 0 -flanking sequence of the NPPB gene has regulatory effect on the expression of the gene. The knockout sequences included a CT-rich zone ( À 1248 to À 1191) and an Alu sequence ( À 1190 to À 934). 18 Kosuge et al. reported that a variable number of tandem repeat (VNTR) polymorphism, a tandem repeat of the four-nucleotide sequence TTTC at the 5 0 -flanking sequence of NPPB, was correlated with primary hypertension in Japanese females; the frequency of the 16-repeat allele was significantly lower in the essential hypertension group (6.5%) than in the group with normal BP (12.2%, P ¼ 0.046). Recently, Chen et al. 17 reported that the BNP rs198388 polymorphism may be associated with the Chinese Han ancestry. A normal individual carrying a c.-1190 G4T singlenucleotide polymorphism was also identified in our study. It would appear worthwhile to conduct further studies of the relationship between this single-nucleotide polymorphism and hypertension.
Sodium nitroprusside is a fast acting vasodilator with a short duration of action that exerts a direct dilatory effect on artery and vein smooth muscle via increased NO production in vascular endothelial cells, and also acts on the renin-angiotensinaldosterone system. 28, 29 In our study, sodium nitroprusside effectively reduced BP and it also significantly reduced the level of plasma BNP in hypertensive patients with the normal NPPB gene. These observations imply that reduction of BNP level by sodium nitroprusside might have role in sodium nitroprussideinduced BP reduction. The hypertensive patients with the complex mutation at the 5 0 -flanking sequence of NPPB had a low level of plasma BNP, and sodium nitroprusside did not affect the level of plasma BNP in this group. It might be the reason why these patients exhibited a significantly lower rate of change in BP after treatment with the drug. The study of genomics has the potential for the identification of new markers of cardiovascular disease and genetic tests that can predict drug efficacy. 30 Identification of mutations in the NPPB gene that are associated with decreased sensitivity to sodium nitroprusside may affect the strategy for clinical management of patients with malignant hypertension.
A limitation of this study is that only the antihypertensive agent sodium nitroprusside was studied. Currently available vasodilators include nitroglycerin, nitroprusside and nesiritide. Among them, nitroprusside is a balanced arterial and venous vasodilator with a very short half-life, which facilitates rapid titration. Sodium nitroprusside is widely advocated as a first-line agent in the treatment of malignant hypertension. 31 Thus, we selected sodium nitroprusside for use in this study.
CONCLUSIONS
In summary, a complex mutation of the NPPB gene might be an etiological factor of hereditary malignant hypertension, and it is associated with low sensitivity to the antihypertensive effect of sodium nitroprusside.
What is known about this topic
Genetic factors account for 30-50% of cases of primary hypertension. BNP promotes sodium elimination and urination.
Mutations of the NPPB are associated with cardiovascular disease.
What this study adds Mutations in the 5 0 -flanking region of the NPPB gene were detected in three patients of a hypertensive family who were less sensitive to sodium nitroprusside treatment. Sporadic hypertension patients without the NPPB gene mutation were sensitive to sodium nitroprusside treatment. BNP levels of patients with the complex mutation were significantly lower than that of sporadic hypertension patients.
